Introduction: Our goal was to study whether influenza vaccination induced antibody mediated rejection in a large cohort of solid organ transplant recipients (SOTR). Methods: Serum anti-Human Leukocyte Antigen (HLA) antibodies were determined using class I and class II antibody-coated latex beads (FlowPRATM Screening Test) by flow cytometry. Anti-HLA antibody specificity was determined using the single-antigen bead flow cytometry (SAFC) assay and assignation of donor specific antibodies (DSA) was performed by virtual-crossmatch. Results: We studied a cohort of 490 SOTR that received an influenza vaccination from 2009 to 2013: 110 (22.4%) received the pandemic adjuvanted vaccine, 59 (12%) within the first 6 months post-transplantation, 185 (37.7%) more than 6 months after transplantation and 136 (27.7%) received two vaccination doses. Overall, no differences of anti-HLA antibodies were found after immunization in patients that received the adjuvanted vaccine, within the first 6 months post-transplantation, or based on the type of organ transplanted. However, the second immunization dose increased the percentage of patients positive for anti-HLA class I significantly compared with patients with one dose (14.6% vs. 3.8%; P = 0.003). Patients with pre-existing antibodies before vaccination (15.7% for anti-HLA class I and 15.9% for class II) did not increase reactivity after immunization. A group of 75 (14.4%) patients developed de novo anti-HLA antibodies, however, only 5 (1.02%) of them were DSA, and none experienced allograft rejection. Only two (0.4%) patients were diagnosed with graft rejection with favorable outcomes and neither of them developed DSA. Conclusion: Our results suggest that influenza vaccination is not associated with graft rejection in this cohort of SOTR.
Graft Rejection/immunology , HLA Antigens/immunology , Influenza Vaccines/therapeutic use , Isoantibodies/blood , Organ Transplantation/adverse effects , Biomarkers/blood , Female , Flow Cytometry , Graft Rejection/blood , Graft Rejection/diagnosis , Histocompatibility , Histocompatibility Testing , Humans , Influenza Vaccines/adverse effects , Longitudinal Studies , Male , Middle Aged , Prospective Studies , Risk Assessment , Risk Factors , Spain , Time Factors , Treatment Outcome , Vaccination
SCOPE: Systemic lupus erythematosus (SLE) is a chronic multiorgan autoimmune disease characterized by immune deregulation, which involves altered T-cell response and imbalance of cytokine production. The phenolic fraction (PE) of extra virgin olive oil (EVOO) possesses anti-inflammatory and immunomodulatory properties and exerts preventive effects in murine models of immune-inflammatory diseases, such as SLE. The present study was designed to determine the in vitro effects of the PE from EVOO on peripheral blood mononuclear cells (PBMC) from inactive patients with SLE and healthy donors. METHODS AND RESULTS: T-cell phenotype was investigated by flow cytometry, cytokine levels were determined by ELISA, and protein expression was detected by Western blot. The PE of EVOO decreased the frequency of CD69+ cells and the secretion of IFN-γ, TNF-α, IL-6, IL-1ß, and IL-10. Moreover, PE increased the expression of I-kappa-B-α and decreased extracellular signal regulated kinase phosphorylation on PBMC from patients with SLE and healthy donors. CONCLUSION: PE modulates cytokine production and attenuates induced T-cell activation, probably through NF-κB signaling pathway, providing the first evidence that PE from EVOO has an anti-inflammatory and immunomodulatory role in SLE patients and it might therefore be considered as a dietary complement in SLE management.
Lupus Erythematosus, Systemic/diet therapy , Olive Oil/chemistry , Phenols/pharmacology , T-Lymphocytes/drug effects , Adult , Apoptosis/drug effects , Case-Control Studies , Cytokines/metabolism , Humans , Leukocytes, Mononuclear/drug effects , Middle Aged , NF-kappa B/metabolism , Phenols/chemistry , T-Lymphocytes/physiology
INTRODUCTION: A study was conducted to determine whether the human leukocyte antigen (HLA) B alleles are implicated in the susceptibility to Henoch-Schönlein purpura (HSP) in the largest series of Caucasian HSP patients ever assessed for genetic studies. METHODS: The study population was composed of 349 Spanish patients diagnosed with HSP fulfilling the American College of Rheumatology and the Michel et al. classification criteria, and 335 sex and ethnically matched controls. HLA-B phenotypes were determined by sequencing-based typing (SBT) and analyzed by chi-square or Fisher exact test. RESULTS: A statistically significant increase of HLA-B*41:02 allele in HSP patients when compared with controls was found (8.3% versus 1.5% respectively; P = 0.0001; OR (odds ratio) =5.76 [2.15-19.3]). These results remained statistically significant after adjusting for Bonferroni correction (P = 0.0028). An internal validation also confirmed the susceptibility effect on HSP associated with HLA-B*41:02 (OR = 5.70 [1.98-16.44]). Since a former study described an association between HLA-DRB1*01:03 and HSP susceptibility, we also evaluated the implication of HLA-B*41:02 independently of HLA-DRB1*01:03. Interestingly, the association remained statistically significant (P = 0.0004, OR = 4.97 [1.8-16.9]). No HLA-B association with specific HSP clinical features was found. CONCLUSIONS: Our study indicates that HLA-B*41:02 is associated with the susceptibility to HSP in Spanish patients irrespective of HLA-DRB1 status.
Genetic Association Studies , Genetic Predisposition to Disease/genetics , HLA-B Antigens/genetics , HLA-DRB1 Chains/genetics , IgA Vasculitis/epidemiology , IgA Vasculitis/genetics , Adolescent , Child , Child, Preschool , Female , Follow-Up Studies , Genetic Association Studies/methods , Humans , IgA Vasculitis/diagnosis , Male , Spain/epidemiology , Young Adult
Objective: Henoch-Schönlein purpura (HSP) is the most common vasculitis in children but it is not exceptional in adults. Increased familial occurrence supports a genetic predisposition for HSP. In this context, an association with the human leukocyte antigen-HLA-DRB1*01 phenotype has been suggested in Caucasian individuals with HSP. However, data on the potential association of HSP with HLA-DRB1*01 were based on small case series. To further investigate this issue, we performed HLA-DRB1 genotyping of the largest series of HSP patients ever assessed for genetic studies in Caucasians. Methods: 342 Spanish patients diagnosed with HSP fulfilling the American College of Rheumatology and the Michel et al classification criteria, and 303 sex and ethnically matched controls were assessed. HLA-DRB1 alleles were determined using a PCR-Sequence-Specific-Oligonucleotide Probe (PCR-SSOP) method. Results: A statistically significant increase of HLA-DRB1*01 in HSP patients when compared with controls was found (43% vs 7%, respectively; p<0.001; odds ratio-OR=2.03 [1.43-2.87]). It was due to the increased frequency of HLA-DRB1*0103 phenotype in HSP (14% vs 2%; p<0.001; OR=8.27 [3.46-23.9]). These results remained statistically significant after adjusting for Bonferroni correction. In contrast, a statistically significant decreased frequency of the HLA-DRB1*0301 phenotype was observed in patients compared to controls (5.6% vs 18.1%, respectively; p<0.001, OR=0.26 [0.14-0.47]), even after adjustment for Bonferroni correction. No HLA-DRB1 association with specific features of the disease was found. Conclusion: Our study confirms an association of HSP with HLA-DRB1*01 in Caucasians. Also, a protective effect against the development of HSP appears to exist in Caucasians carrying the HLA-DRB1*03 phenotype. This article is protected by copyright. All rights reserved.
Fundamento y objetivos: Estudios norteamericanos han encontrado asociación entre pars planitis y el antígeno leucocitario humano (HLA) DR15. Esta situación no está aclarada en la población española. Los objetivos del presente estudio fueron la descripción de los datos clínicos y epidemiológicos en pacientes con pars planitis de nuestra área y determinar la frecuencia de esclerosis múltiple y HLA tipo I y II. Pacientes y método:De 226 pacientes con uveítis valorados desde enero de 1992 hasta octubre de 2005 en el servicio de oftalmología de nuestro centro, 24 cumplieron criterios diagnósticos de pars planitis. Se realizó estudio de HLA I y II a los 24 pacientes y a 194 controles sanos.Resultados: La complicación más frecuente fue el edema macular quístico. La mayoría de pacientes precisó varios tratamientos médicos. No se encontró asociación estadísticamente significativa entre nuestros pacientes y el HLA.Conclusiones: Los datos epidemiológicos coinciden con estudios previos. Parece no existir asociación entre el HLA tipo I y II con la pars planitis en nuestra población. No obstante, el pequeño tamaño de la muestra podría limitar el poder de este estudio (AU)
Background and objectives: Epidemiological studies on North American patients reported an association between HLA DR15 and pars planitis. This association has not been studied in the Spanish population. The objectives of the present study were to describe the clinical and epidemiological features of patients with pars planitis diagnosed in our hospital as well as the prevalence of multiple sclerosis and HLA class I and II.Patients and Methods: Twenty four patients with pars planitis were identified among 226 patients with uveitis diagnosed in the Ophtahlmology Department of our center from January 1992 to October 2006. Twenty four patients and 194 healthy controls underwent HLA A, B and DR genotyping.Results: The most frequent complication was cystic macular edema. Most patients needed many medical treatments. No statistical association was found between pars planitis and HLA.Conclusions: Epidemiological data were consistent with previously reported studies. There appears to be no association between the occurrence of pars planitis and HLA DR 15 or other known HLA genotypes in Spanish patients. However, the small sample size could have limited the power of this study (AU)
Humans , Uveitis/genetics , Pars Planitis/epidemiology , HLA-A1 Antigen/analysis , HLA-A2 Antigen/analysis , Case-Control Studies
BACKGROUND AND OBJECTIVES: Epidemiological studies on North American patients reported an association between HLA DR15 and pars planitis. This association has not been studied in the Spanish population. The objectives of the present study were to describe the clinical and epidemiological features of patients with pars planitis diagnosed in our hospital as well as the prevalence of multiple sclerosis and HLA class I and II. PATIENTS AND METHODS: Twenty four patients with pars planitis were identified among 226 patients with uveitis diagnosed in the Ophtahlmology Department of our center from January 1992 to October 2006. Twenty four patients and 194 healthy controls underwent HLA A, B and DR genotyping. RESULTS: The most frequent complication was cystic macular edema. Most patients needed many medical treatments. No statistical association was found between pars planitis and HLA. CONCLUSIONS: Epidemiological data were consistent with previously reported studies. There appears to be no association between the occurrence of pars planitis and HLA DR 15 or other known HLA genotypes in Spanish patients. However, the small sample size could have limited the power of this study.
Pars Planitis , Female , HLA Antigens/immunology , Humans , Male , Pars Planitis/diagnosis , Pars Planitis/epidemiology , Pars Planitis/immunology , Retrospective Studies , Young Adult
Fundamento y objetivo: El bloqueo auriculoventricular completo (BAVC) congénito se debe, en la mayoría de los pacientes, a lesión del sistema de conducción por anticuerpos trasplacentarios de origen materno (lupus neonatal). En el adulto con lupus eritematoso sistémico (LES) es muy dudosa la cardiotoxicidad por dichos anticuerpos y se ha relacionado con el tratamiento con antipalúdicos de síntesis (APS). Se valora, en nuestro medio, la presencia de BAVC (no congénito) en pacientes adultos con LES y su posible asociación con el tratamiento con APS. Pacientes y métodos: Se ha estudiado la frecuencia de BAVC en una serie de 595 pacientes afectados de LES controlados en una unidad de enfermedades sistémicas. Resultados: Cinco mujeres (0,8% del total) presentaron un BAVC (desarrollado en una crisis lúpica en 2 pacientes). Todas estaban en tratamiento con APS (el 100 frente al 60% en el resto de la serie) y mantuvieron una dosis de 250 mg/día (excepto una, con dosis de 500 mg/día) por un tiempo medio de 90 meses. La dosis media acumulada de APS fue de 753 g. Tres pacientes desarrollaron insuficiencia cardíaca; 2, nefropatía; 2, miopatía; y una, maculopatía. Como procesos acompañantes se constató síndrome de Sjögren (2) e hipotiroidismo (3). La frecuencia de HLA DR3, 80% de los casos, es superior a la observada en la serie total, 34% (p = 0,053). Conclusiones: Constatamos la presencia de BAVC en el 0,8% de pacientes con LES. Todos ellos en tratamiento con APS. No hemos comprobado relación con anticuerpos anti-ENA (anti-Ro y anti-RNP) comunicada en algunos casos, pero sí una tendencia a la asociación con HLA DR3 (en el límite de significación estadística)(AU)
Background and objective: Congenital complete atrioventricular heart block (CHB) is due to the lesion of the cardiac conduction system by specific transplacental antibodies of maternal origin. In adults with systemic lupus erythematosus (SLE), cardiac toxicity is very questionable and has been related to treatment with synthetic antimalarial drugs (AM). Here we evaluate, in our geographic area, the presence of non congenital CHB in adult patients with SLE and its possible association with AM treatment. Patients and methods: The frequency of CHB has been studied revising the clinical records of 595 SLE patients followed at the Unit for Systemic Diseases. Results: Five women (0.8% of the total series) suffered from CHB (2 patients developed it during a lupic crisis). All were on treatment with AM (100 versus 60% of the rest of the series) and maintained a dose of 250 mg/day (except one, with a dose of 500 mg/day) for a mean period of 90 months. The accumulated mean dose of AM was 753 g. Three patients developed cardiac insufficiency; 2 nephropathy; 2 myopathy; and one maculopathy. As accompanying processes we detected Sjögrens syndrome (2) and hypothyroidism (3). The frequency of HLA DR3, positive in 80% of the cases, is higher than observed in the total series, 34% (p = 0.053). Conclusions: We detected the presence of CHB in 0.8% of SLE patients. They were all treated with AM. We did not verify any relationship with anti-ENA (anti-Ro/La and anti-RNP) antibodies, as communicated by others, but rather a trend to the association with HLA DR3 (at the limit of statistical significance)(AU)
Humans , Male , Female , Adult , Atrioventricular Block/chemically induced , Lupus Erythematosus, Systemic/complications , Antimalarials/adverse effects , Cardiotoxins/adverse effects
BACKGROUND AND OBJECTIVE: Congenital complete atrioventricular heart block (CHB) is due to the lesion of the cardiac conduction system by specific transplacental antibodies of maternal origin. In adults with systemic lupus erythematosus (SLE), cardiac toxicity is very questionable and has been related to treatment with synthetic antimalarial drugs (AM). Here we evaluate, in our geographic area, the presence of non congenital CHB in adult patients with SLE and its possible association with AM treatment. PATIENTS AND METHODS: The frequency of CHB has been studied revising the clinical records of 595 SLE patients followed at the Unit for Systemic Diseases. RESULTS: Five women (0.8% of the total series) suffered from CHB (2 patients developed it during a lupic crisis). All were on treatment with AM (100 versus 60% of the rest of the series) and maintained a dose of 250 mg/day (except one, with a dose of 500 mg/day) for a mean period of 90 months. The accumulated mean dose of AM was 753 g. Three patients developed cardiac insufficiency; 2 nephropathy; 2 myopathy; and one maculopathy. As accompanying processes we detected Sjögren's syndrome (2) and hypothyroidism (3). The frequency of HLA DR3, positive in 80% of the cases, is higher than observed in the total series, 34% (p = 0.053). CONCLUSIONS: We detected the presence of CHB in 0.8% of SLE patients. They were all treated with AM. We did not verify any relationship with anti-ENA (anti-Ro/La and anti-RNP) antibodies, as communicated by others, but rather a trend to the association with HLA DR3 (at the limit of statistical significance).
BACKGROUND: The long-term outcome of kidney transplantation could be influenced by the appearance of antibodies against donor-specific antigens. Glutathione S-transferase T1 (GSTT1) is a protein preferentially expressed in liver and kidney cells. Deletion of the GSTT1 gene results in a complete lack of protein expression, which occurs in 20% of the white population. GSTT1 donor-recipient mismatch has been deleterious in liver transplantation. The purpose of this study is to examine immunologic and clinical consequences of a GSTT1 donor-recipient mismatch in kidney transplantation. METHODS: The presence of anti-GSTT1 antibodies was studied retrospectively in sera from 135 patients who underwent transplantation before 1995. Samples from 89 patients who received a GSTT1-positive kidney graft between December 1998 and May 2001 were collected prospectively. GSTT1 genotypes and anti-GSTT1 antibodies were studied by using standard methods. RESULTS: Seven patients, all with the null genotype, produced anti-GSTT1 antibodies. No transplant recipient with a positive genotype produced these antibodies. Six of 7 patients with antibodies also were positive for hepatitis C virus. Clinical outcomes of these patients did not differ from those of the entire group. CONCLUSION: After kidney transplantation, some patients with the null GSTT1 genotype who received a GSTT1-positive graft developed an immune response, with production of anti-GSTT1 antibodies. The presence of these antibodies did not seem to produce functional impairment in the graft. Hepatitis C virus seems to have a prominent role in this particular allograft immune response.
Glutathione Transferase/immunology , Isoantibodies/biosynthesis , Isoantigens/immunology , Kidney Transplantation/immunology , Transplantation, Homologous/immunology , Adult , Female , Genotype , Glutathione Transferase/genetics , Hepatitis C/complications , Hepatitis C Antibodies/blood , Humans , Isoantibodies/blood , Isoantibodies/immunology , Kidney/enzymology , Kidney/immunology , Kidney Failure, Chronic/immunology , Kidney Failure, Chronic/surgery , Male , Prospective Studies , Retrospective Studies , Tissue Donors , Treatment Outcome
OBJECTIVE: The A allele of the PD1.3 single-nucleotide polymorphism (SNP) on the programmed cell death gene PDCD1 was markedly more frequent in patients with systemic lupus erythematosus (SLE) than in unaffected controls in a recent study involving large sets of Swedish, European American, and Mexican families. This study sought to determine the role of PDCD1 in susceptibility to SLE in the Spanish population. METHODS: Seven PDCD1 SNPs were studied in 518 SLE patients and 800 healthy control subjects who had been recruited in 5 distant towns spanning continental Spain. Patients and controls were of Spanish ancestry. The diagnosis of SLE was in accordance with the American College of Rheumatology updated classification criteria. RESULTS: The A allele of the PD1.3 polymorphism was significantly less frequent in Spanish female patients with SLE than in Spanish female controls (9.0% versus 13.0%, odds ratio 0.67, 95% confidence interval 0.50-0.89). This difference was consistent across the 5 sets of samples grouped by town of recruitment. The other PDCD1 SNPs were not associated with SLE susceptibility. The haplotype structure of PDCD1 in the Spanish controls was different from that reported in other healthy control populations. CONCLUSION: Our results confirm the association of PDCD1 with susceptibility to SLE, but the findings show a lack of involvement of the PD1.3 SNP, which is contrary to the role of the PD1.3 A allele observed previously. These contradictory results probably reflect population differences in the haplotype structure of the PDCD1 locus. More research focusing on new polymorphisms and identifying associations in other populations will be needed to clarify the role of PDCD1 in SLE susceptibility.
Antigens, Surface/genetics , Genetic Predisposition to Disease/genetics , Lupus Erythematosus, Systemic/genetics , Alleles , Antigens, CD , Apoptosis Regulatory Proteins , Female , Humans , Male , Polymorphism, Single Nucleotide , Programmed Cell Death 1 Receptor , Spain , White People/genetics
OBJECTIVE: To examine immunogenetic and clinical features in a series of patients with the idiopathic tubulointerstitial nephritis and uveitis (TINU) syndrome diagnosed at the single referral hospital for a defined population in Southern Spain. PATIENTS AND METHODS: Retrospective study of the case records of all patients diagnosed with the TINU syndrome in the Departments of Ophthalmology and Medicine of the Valme University Hospital (Seville, Spain) from January 1996 through October 2000. Patients were included in this study if they had a renal biopsy showing interstitial edema and infiltration by lymphocytes, plasma cells, macrophages, eosinophils, and neutrophils. In these cases fibrosis was occasionally seen, but no glomerular changes were found. In addition, a diagnosis of uveitis by expert ophthalmologists was always required. Underlying diseases, which might be responsible for the renal or ocular manifestations, were excluded. Patients were HLA-DRB1 genotyped from DNA by using molecular-based methods. RESULTS: Six patients (4 females) fulfilled the definitions described above. Four were younger than 18 years. In addition to tubulointerstitial nephritis, non-granulomatous uveitis (anterior or panuveitis) associated with low visual acuity was present at the time of diagnosis. Leukocytosis and increase of acute phase reactants were also commonly observed at the time of diagnosis. Topical and oral corticosteroids were prescribed to all the patients. Cyclosporine A therapy was required in 2 cases. After a 2.5-year median follow-up, visual acuity had improved in all cases. Of note, 4 of 6 patients carried the HLA-DRB1*01 allele. CONCLUSION: The TINU syndrome should be considered in the differential diagnosis of patients presenting with visual and renal manifestations. The presence of renal dysfunction in patients with uveitis may be of some help, as a warning sign, for the recognition of patients who require a rapid diagnosis and therapy. In Southern Spain, the TINU syndrome appears to be associated with HLA-DRB1*01 allele.
Nephritis, Interstitial/diagnosis , Nephritis, Interstitial/epidemiology , Uveitis/diagnosis , Uveitis/epidemiology , Administration, Oral , Administration, Topical , Adolescent , Adrenal Cortex Hormones/therapeutic use , Adult , Age Distribution , Child , Comorbidity , Female , Humans , Incidence , Male , Nephritis, Interstitial/drug therapy , Prognosis , Retrospective Studies , Risk Factors , Sex Distribution , Spain/epidemiology , Syndrome , Treatment Outcome , Uveitis/drug therapy
